-
公开(公告)号：US20210087230A1
公开(公告)日：2021-03-25
申请号：US16772178
申请日：2018-12-14
发明人： VINCENT MARION
摘要： The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.
-
2.发明公开公开(公告)号：US20230340021A1
公开(公告)日：2023-10-26
申请号：US18067760
申请日：2022-12-19
发明人： VINCENT MARION
CPC分类号： C07K7/08 , A61P1/16 , A61K38/45 , C12N9/12 , C12Y207/11013 , A61K38/16 , C07K14/00 , A61K38/00
摘要： The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.
-
公开(公告)号：US20220133860A1
公开(公告)日：2022-05-05
申请号：US17415796
申请日：2019-12-20
发明人： VINCENT MARION
摘要： The present invention relates to peptides for the treatment of diabetes and associated disorders.
-
公开(公告)号：US20200368314A1
公开(公告)日：2020-11-26
申请号：US16636040
申请日：2018-08-03
申请人： UNIVERSITE DE STRASBOURG , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , VAXINE PTY LTD
发明人： VINCENT MARION , NIKOLAI PETROVSKY
摘要： The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma.
-
公开(公告)号：US20200216504A1
公开(公告)日：2020-07-09
申请号：US16627389
申请日：2018-06-29
申请人： UNIVERSITE DE STRASBOURG , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , VAXINE PTY LTD
发明人： VINCENT MARION , NIKOLAI PETROVSKY
摘要： The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.
-
公开(公告)号：US20170231930A1
公开(公告)日：2017-08-17
申请号：US15582787
申请日：2017-05-01
发明人： VINCENT MARION , ANAIS MOCKEL , HELENE DOLLFUS
IPC分类号： A61K31/155 , A61K9/00 , A61K31/19
CPC分类号： A61K38/07 , A61K9/0048 , A61K31/155 , A61K31/19 , A61K38/2278 , A61K38/55 , A61K45/00 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2α, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2α and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.
-
公开(公告)号：US20210069301A1
公开(公告)日：2021-03-11
申请号：US17074658
申请日：2020-10-20
申请人： UNIVERSITE DE STRASBOURG , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , VAXINE PTY LTD
发明人： VINCENT MARION , NIKOLAI PETROVSKY
摘要： The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by αPKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of αPKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of αPKC on ALMS1.
-
公开(公告)号：US20170000857A1
公开(公告)日：2017-01-05
申请号：US15114080
申请日：2015-01-29
申请人： UNIVERSITE DE STRASBOURG , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , VAXINE PTY LTD
发明人： VINCENT MARION , NIKOLAI PETROVSKY
摘要： The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by αPKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of αPKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of αPKC on ALMS1.
摘要翻译： 本发明涉及通过GLUT4分选囊泡调节胰岛素介导的葡萄糖摄取以及通过αPKC下调ALMS1的ALMS1的鉴定。 因此，本发明涉及能够防止αPKC与ALMS1结合用于治疗或预防糖尿病，特别是2型糖尿病的分子。 另外，本发明涉及一种鉴定能够防止αPKC与ALMS1结合的分子的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)
